Timeline Entry
On 26 September 1818 in London, the physician and obstetric lecturer James Blundell injected human blood into a man identified in the published record as Brazier. The patient rallied briefly but died fifty-six hours later. The procedure is important as the first well-documented human-to-human transfusion, not as a successful cure (Blundell 1819; Dzik 2018).
Blundell's achievement was to connect animal experiment, human donor blood, purpose-built syringes, and replacement of severe blood loss. The first published survivals came seven years later, in collaborative obstetric cases reported by Charles Waller and Edward Doubleday. Even those recoveries preceded blood groups, cross-matching, anticoagulation, sterile collection, storage, and organized donor services.
Historical Significance
Calling the 1818 event the “first successful blood transfusion” collapses three different claims: first well-documented use of human blood, temporary physiological response, and survival. The record supports the first two. It does not support the third. Separating them makes Blundell's contribution more accurate rather than less important.
Blundell's dog experiments persuaded him that blood from another species could not safely substitute in large quantities. He therefore used only human blood in people—a major change from the lamb- and calf-blood experiments of the seventeenth century (Blundell 1818; Nguyen and Desai 2020).
Blundell was moved by deaths from uterine “flooding,” the period's common term for severe obstetric bleeding. He framed transfusion as replacement of something lost, especially in otherwise hopeless hemorrhage, rather than as a way to alter temperament or expel diseased blood (Schmidt and Leacock 2002; Dzik 2018).
A donor had to be present, a vein exposed, blood collected and injected before it clotted, and the quantity judged during an emergency. No test could identify ABO incompatibility. The 1818 work established a clinical problem and a possible technique, not reproducible safety.
Before 1818
William Harvey's 1628 account of the circulation of blood made transfer between vessels experimentally intelligible. In Oxford in 1665, Richard Lower passed blood directly from one dog to another; his method was reported to the Royal Society in 1666. Jean-Baptiste Denis in Paris and Lower and Edmund King in London then transfused animal blood into people in 1667. These were not early versions of modern hemorrhage care: experimenters also hoped that blood might change illness, vitality, or disposition (Royal Society; Nguyen and Desai 2020).
Severe reactions, a death after Denis's treatment of Antoine Mauroy, legal proceedings, and restrictions helped discredit the practice. Yet the usual story of total silence for 150 years is too simple. Physiologists continued to consider transfusion, and the idea returned through networks extending beyond London. John Henry Leacock, a medical student from Barbados at the University of Edinburgh, argued in his 1816 dissertation and a 1817 paper that transfusion should use blood of the same species and might answer extreme hemorrhage. Blundell explicitly credited Leacock with prompting his own inquiry; Leacock left no record of attempting transfusion in a person. The historical reconstruction identifies him as a sugar planter's son, so the education that carried his ideas from Barbados to Edinburgh also belonged to an Atlantic world structured by plantation wealth and slavery (Schmidt and Leacock 2002).
Blundell taught physiology and midwifery at Guy's Hospital. That combination mattered. Animal experiments addressed whether venous blood, delay, air, and contact with a syringe destroyed blood's restorative capacity; obstetric practice supplied the urgent clinical problem of patients collapsing after childbirth. Instrument makers supplied the precision-made devices that joined those settings (Young 1964; Dzik 2018).
Chronology
The 1818 Case
Blundell's 1819 case report identifies the patient by the surname Brazier and describes him as between thirty and forty years old. He had endured months of persistent vomiting and was thought to have “scirrhosity of the pylorus.” Scirrhous was a period pathological term for a hard growth, often cancerous; modern historians interpret this description as malignant obstruction at the stomach outlet. That retrospective diagnosis is plausible, not laboratory confirmation from 1818 (Blundell 1819; Dzik 2018).
Blood from several men present was collected in small amounts, drawn into a syringe, and injected through a cannula into a vein in Brazier's arm. The report gives a total of twelve to fourteen fluid ounces—roughly 340 to 400 millilitres—over thirty to forty minutes. The estimate should not be read as a modern measured dose: collection, spillage, and clotting made the amount actually entering the patient uncertain.
Brazier's pulse, warmth, colour, and ability to take food appeared to improve. He then declined and died fifty-six hours after transfusion. The report documents a temporary change after treatment, but it cannot show how much was caused by blood, whether incompatible blood from one or more donors harmed him, or whether any intervention could have reversed his underlying disease. Survival is therefore the clearest boundary: the 1818 transfusion was attempted and physiologically eventful, but not successful in the sense normally understood by readers today.
The 1825 Cases
Waller's 1825 pamphlet describes two patients with severe uterine hemorrhage, both treated through the City of London and Southwark Midwifery Institution. In the first case, Waller summoned Blundell, consulted at the bedside, exposed a vein at the patient's elbow, and used a tinned brass syringe holding two fluid ounces. Her husband agreed to supply blood, which ran into an ordinary glass tumbler and was immediately drawn into the syringe. After two injections the practitioners stopped at four ounces because of transient faintness and irregular pulse. Waller reported recovery (Waller 1825).
Doubleday managed the second case and sought Blundell's assistance. The patient resisted strongly enough that the first attempt was abandoned; roughly five hours later, after further decline, Doubleday proceeded and reported injecting fourteen ounces. She too survived. The source makes the woman's resistance visible but records no sustained consent discussion. That silence cannot prove what was or was not said at the bedside; it does show the limits of a practitioner account written to defend a disputed procedure.
Waller attributed both recoveries to blood because the patients' rallies lasted whereas earlier responses to brandy, ammonia, warmth, food, and other measures had not. This was a reasoned contemporary comparison, not a controlled test. The women were unnamed, multiple treatments were given, observations were made by advocates, and no laboratory data could establish compatibility. “Successful” here means that the patient survived after the procedure; it does not prove that transfusion alone caused recovery or that the method was generally safe.
Material Practice
Early indirect transfusion meant opening a donor's vein, catching blood in a cup, filling a syringe, expelling air, and injecting it into an exposed recipient vein. A husband supplied blood in Waller's 1825 case; Blundell's assistants and observers supplied it for Brazier. Donation was immediate, directed, and embedded in family and professional authority.
Blundell tested syringes because direct artery-to-vein connection was difficult. London makers including Laundy and Lloyd turned physiological ideas into working apparatus. Syringes, the “Impellor,” and later the “Gravitator” tried to limit delay, contact with air, and clotting, but clots could still block the device and the delivered volume remained uncertain (Dzik 2018; Pelis 1997).
Blundell correctly rejected animal blood for human recipients, but people are not immunologically interchangeable. Without ABO typing or cross-matching, a donor-recipient pairing could produce acute red-cell destruction. Small or incompletely delivered volumes may partly explain why reactions were not always recognized in already moribund patients (Nguyen and Desai 2020).
Evidence And Ethics
Blundell and Waller wrote to persuade medical colleagues that transfusion could be rational and technically possible. Their reports are valuable because they give times, instruments, approximate quantities, symptoms, other remedies, and outcomes. They are also advocacy texts. Improvement could be credited to transfusion, while failure could be explained by late treatment or irreversible disease. Modern historians should neither accept those causal judgments uncritically nor dismiss all nineteenth-century use simply because blood groups were unknown (Pelis 1997).
The asymmetry of the record matters. Physicians, instrument makers, and some male donors can be named; the two women whose recoveries established the therapy appear chiefly through age, physical description, marital status, symptoms, and reported speech. Brazier's first name is not supplied. These omissions limit what can be said about patient understanding, choice, and later experience. A desperate prognosis does not itself answer those questions.
Animal experimentation was also essential to the method and was defended by Blundell within the moral assumptions of his own profession. Dogs were bled to collapse, transfused, and sometimes killed in tests of timing and species difference. Recording that material cost is part of the history; it should not be hidden behind a heroic story of discovery (Blundell 1818; Young 1964).
Nineteenth-Century Debate
A simple progress story moves from Blundell directly to Landsteiner. The nineteenth century was less tidy. British obstetricians continued to report transfusions, especially for uterine hemorrhage, while debating when to act, whether to use whole or defibrinated blood, how much to give, and which apparatus best controlled clotting. Later practitioners also tried saline, milk, and—despite Blundell's warning—animal blood. Kim Pelis argues that the practice must be understood through these contemporary problems rather than dismissed in advance as futile because blood groups were unknown (Pelis 1997; Learoyd 2012).
Reported recoveries did not settle causation or safety. Transfusion remained uncommon, difficult, and controversial; clotting obstructed instruments, acute reactions were poorly understood, and saline infusion offered a simpler way to restore circulating volume in some emergencies. By the century's end, professional opinion remained divided. Blundell's work had made transfusion a serious clinical possibility, not an inevitable standard of care.
Legacy
In 1901 Karl Landsteiner published evidence that human blood could be divided into groups according to agglutination reactions; a fourth major ABO group was soon described. This explained a central danger that Blundell could not see. Typing and cross-matching made donor selection more rational, but they were only part of the transformation (Nobel Foundation; Coller 2015).
Citrate anticoagulation, refrigeration, preservative solutions, containers, donor screening, and record systems allowed blood to be collected before an emergency and moved to patients rather than bringing a donor to every bedside. Oswald Robertson's use of stored, citrated blood near the Western Front in 1917 illustrates this institutional change. Twentieth-century blood banks and national services then made transfusion scalable while creating new questions about donor recruitment, infection, allocation, and state responsibility.
The durable legacy of 1818 is therefore specific. Blundell and his wider network demonstrated a documented human-blood procedure, developed a replacement rationale, and created tools for immediate transfer. The event did not save Brazier, establish the first surviving case, reveal blood groups, or create modern transfusion medicine by itself.
Reading Path
Read Blood Circulation for the physiological premise and History of Obstetrics and Midwifery for the maternal-care setting in which early human transfusion acquired its strongest indication.
Primary Sources
Philosophical Transactions 1 (1666): 353–358. doi:10.1098/rstl.1665.0128. The Royal Society catalogue describes the manuscript and its publication. It documents dog-to-dog technique, not a human transfusion or modern therapeutic safety.
Medico-Chirurgical Transactions 9, pt. 1 (1818): 56–92. doi:10.1177/09595287180090p107. Read to the society on 3 February 1818, this is the main record of Blundell's animal experiments, species argument, and syringe reasoning. It predates the Brazier procedure.
Medico-Chirurgical Transactions 10, pt. 2 (1819): 296–311. doi:10.1177/09595287190100p204. Read on 22 December 1818, this practitioner-authored report supplies the clinical sequence and fifty-six-hour outcome. Its purpose was to circulate an experimental remedy, and it cannot determine treatment effect or compatibility.
London: W. Jackson, 1825. Digitized from the Royal College of Surgeons of England copy by the Medical Heritage Library. The pamphlet gives unusually concrete bedside and apparatus detail, but it is an advocate's interpretation of two uncontrolled cases and largely withholds the patients' identities and perspectives.
The Lancet 12, no. 302 (13 June 1829): 321–324. A later summary of cases, indications, and apparatus. It shows that Blundell still presented transfusion as a last resort, not settled routine treatment.
References
BMJ 325, no. 7378 (2002): 1485–1487. doi:10.1136/bmj.325.7378.1485. Reconstructs Leacock's Edinburgh work and Blundell's acknowledgment while distinguishing proposal and animal experiment from human treatment.
Medical History 8, no. 2 (1964): 159–169. An account of Blundell's experimental, teaching, and obstetric work. Useful for placing transfusion among his broader practices, though written before later scholarship recovered Leacock and other collaborators in detail.
Transfusion Medicine Reviews 32, no. 4 (2018): 205–212. Reconstructs the 1818 date, the sequence of failed and surviving cases, and the contributions of Leacock, Waller, Doubleday, donors, and instrument makers.
Annals of Science 54, no. 4 (1997): 331–360. doi:10.1080/00033799700200271. A history-of-medicine analysis of coagulation, apparatus, competing fluids, clinical reasoning, and the danger of dismissing all pre-blood-group practice through presentist assumptions.
Transfusion Medicine 22, no. 6 (2012): 372–376. A focused review of Blundell and later nineteenth-century practice, with bibliographic links to contemporary case reports.
Journal of Anesthesia History 6, no. 3 (2020): 127–132. doi:10.1016/j.janh.2020.07.001. Reviews animal-to-human transfusion, its reported reactions and abandonment, and the difficulty early clinicians faced in separating treatment harm from underlying illness.
The official record for the 1930 Nobel Prize explains Landsteiner's 1901 classification of human blood groups and its relation to agglutination. It is used here only for the later compatibility milestone, not as a history of nineteenth-century transfusion.
Blood 126, no. 24 (2015): 2548–2560. doi:10.1182/blood-2015-09-659581. Summarizes the linked development of ABO grouping, cross-matching, citrate anticoagulation, refrigerated storage, and wartime application.